<DOC>
	<DOC>NCT00092898</DOC>
	<brief_summary>This is a 6-month study with patients who have the rare disease, sitosterolemia which may result in heart-related diseases. These patients have unusually high absorption of non-cholesterol sterols, resulting in heart-related diseases. This study investigates whether absorption of these non-cholesterols can be reduced in these patients.</brief_summary>
	<brief_title>An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED)</brief_title>
	<detailed_description>The duration of treatment is 26 weeks.</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Metabolism, Inborn Errors</mesh_term>
	<mesh_term>Lipid Metabolism, Inborn Errors</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>18 years or older, with a history of elevated sitosterol levels and have received treatment for at least 6 months prior to study entry. Patient has a condition which, in the opinion of the investigator, might pose a risk to the patient or interfere with participation in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Sitosterolemia</keyword>
</DOC>